These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 21200314)
21. Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine. Bulotta S; Celano M; Costante G; Russo D Endocrine; 2016 May; 52(2):214-21. PubMed ID: 26690657 [TBL] [Abstract][Full Text] [Related]
22. Medullary thyroid cancer: molecular biology and novel molecular therapies. Cakir M; Grossman AB Neuroendocrinology; 2009; 90(4):323-48. PubMed ID: 19468197 [TBL] [Abstract][Full Text] [Related]
23. Treatment of metastatic renal cell carcinoma. Reeves DJ; Liu CY Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348 [TBL] [Abstract][Full Text] [Related]
24. Pathogenesis of metastatic disease: implications for current therapy and for the development of new therapeutic strategies. Poste G Cancer Treat Rep; 1986 Jan; 70(1):183-99. PubMed ID: 3510734 [TBL] [Abstract][Full Text] [Related]
25. Targeting vascular endothelial growth factor receptor in thyroid cancer: the intracellular and extracellular implications. Keefe SM; Cohen MA; Brose MS Clin Cancer Res; 2010 Feb; 16(3):778-83. PubMed ID: 20103668 [TBL] [Abstract][Full Text] [Related]
26. Microvessel count: an indicator of poor outcome in medullary thyroid carcinoma but not in other types of thyroid carcinoma. Fontanini G; Vignati S; Pacini F; Pollina L; Basolo F Mod Pathol; 1996 Jun; 9(6):636-41. PubMed ID: 8782200 [TBL] [Abstract][Full Text] [Related]
27. Therapeutic strategies in the management of patients with metastatic anaplastic thyroid cancer: review of the current literature. Granata R; Locati L; Licitra L Curr Opin Oncol; 2013 May; 25(3):224-8. PubMed ID: 23493194 [TBL] [Abstract][Full Text] [Related]
28. Redifferentiating agents in non-radioiodine avid cancer. Seregni E; Vellani C; Castellani MR; Maccauro M; Pallotti F; Scaramellini G; Guzzo M; Greco A Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):513-9. PubMed ID: 19910904 [TBL] [Abstract][Full Text] [Related]
29. Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma. Diamantis ML; Chon SY J Drugs Dermatol; 2010 Feb; 9(2):169-71. PubMed ID: 20214183 [TBL] [Abstract][Full Text] [Related]
30. Metastatic thyroid cancer unresponsive to conventional therapies: novel management approaches through translational clinical research. Sarlis NJ Curr Drug Targets Immune Endocr Metabol Disord; 2001 Aug; 1(2):103-15. PubMed ID: 12476792 [TBL] [Abstract][Full Text] [Related]
31. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. Schlumberger MJ; Elisei R; Bastholt L; Wirth LJ; Martins RG; Locati LD; Jarzab B; Pacini F; Daumerie C; Droz JP; Eschenberg MJ; Sun YN; Juan T; Stepan DE; Sherman SI J Clin Oncol; 2009 Aug; 27(23):3794-801. PubMed ID: 19564535 [TBL] [Abstract][Full Text] [Related]
32. Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope. Deshpande HA; Gettinger SN; Sosa JA Curr Opin Oncol; 2008 Jan; 20(1):19-24. PubMed ID: 18043252 [TBL] [Abstract][Full Text] [Related]
33. New systemic treatment options for metastatic renal-cell carcinoma in the era of targeted therapies. Tan TH; Pranavan G; Haxhimolla HZ; Yip D Asia Pac J Clin Oncol; 2010 Mar; 6(1):5-18. PubMed ID: 20398033 [TBL] [Abstract][Full Text] [Related]